Department of Obstetrics and Gynecology, Zhengzhou Key Laboratory of Endometrial Disease Prevention and Treatment Zhengzhou China, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China.
Drug Dev Res. 2024 Sep;85(6):e22260. doi: 10.1002/ddr.22260.
In 2023, the U.S. Food and Drug Administration has approved 29 small molecule drugs. These newly approved small molecule drugs possess the distinct scaffolds, thereby exhibiting diverse mechanisms of action and binding modalities. Moreover, the marketed drugs have always been an important source of new drug development and creative inspiration, thereby fostering analogous endeavors in drug discovery that potentially extend to the diverse clinical indications. Therefore, conducting a comprehensive evaluation of drug approval experience and associated information will facilitate the expedited identification of highly potent drug molecules. In this review, we comprehensively summarized the relevant information regarding the clinical applications, mechanisms of action and chemical synthesis of 29 small molecule drugs, with the aim of providing a promising structural basis and design inspiration for pharmaceutical chemists.
2023 年，美国食品药品监督管理局批准了 29 种小分子药物。这些新批准的小分子药物具有独特的骨架，因此表现出不同的作用机制和结合方式。此外，已上市的药物一直是新药开发和创新灵感的重要来源，从而促进了药物发现中的类似努力，这些努力可能扩展到不同的临床适应症。因此，对药物批准经验和相关信息进行全面评估将有助于快速确定高效药物分子。在这篇综述中，我们全面总结了 29 种小分子药物的临床应用、作用机制和化学合成的相关信息，旨在为药物化学家提供有前途的结构基础和设计灵感。
